Lineage Cell Therapeutics, Inc.
LCTX
$0.5111
$0.02555.25%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.56M | 9.50M | 8.72M | 6.19M | 8.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.56M | 9.50M | 8.72M | 6.19M | 8.00M |
| Cost of Revenue | 12.68M | 12.66M | 13.25M | 13.95M | 15.04M |
| Gross Profit | -3.12M | -3.16M | -4.53M | -7.76M | -7.03M |
| SG&A Expenses | 18.03M | 18.17M | 14.53M | 14.16M | 14.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.88M | 30.98M | 27.92M | 28.25M | 29.23M |
| Operating Income | -21.32M | -21.48M | -19.20M | -22.07M | -21.22M |
| Income Before Tax | -16.17M | -18.58M | -20.05M | -24.20M | -23.63M |
| Income Tax Expenses | -- | -- | 0.00 | 0.00 | 0.00 |
| Earnings from Continuing Operations | -16.17 | -18.58 | -20.05 | -24.20 | -23.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -39.00K | -27.00K | -65.00K | 16.00K | -23.00K |
| Net Income | -16.21M | -18.61M | -20.11M | -24.19M | -23.66M |
| EBIT | -21.32M | -21.48M | -19.20M | -22.07M | -21.22M |
| EBITDA | -20.72M | -20.87M | -18.57M | -21.40M | -20.53M |
| EPS Basic | -0.08 | -0.10 | -0.11 | -0.13 | -0.13 |
| Normalized Basic EPS | -0.05 | -0.06 | -0.06 | -0.07 | -0.07 |
| EPS Diluted | -0.08 | -0.10 | -0.11 | -0.13 | -0.13 |
| Normalized Diluted EPS | -0.05 | -0.06 | -0.06 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 843.89M | 800.75M | 735.57M | 721.60M | 703.38M |
| Average Diluted Shares Outstanding | 843.89M | 800.75M | 735.57M | 721.60M | 703.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |